local_hospital

Romed Klinikum Rosenheim

Address
lock Available on a paid plan

Respiratory Medicine and Pulmonology

At Romed Klinikum Rosenheim, the clinical trial portfolio strongly focuses on respiratory tract diseases, especially chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and severe viral lung infections. The studies are designed to test new therapies, assess symptom control, and improve long-term lung function and outcomes.

  • New treatment options for COPD and exacerbation prevention
  • Therapies aimed at slowing fibrotic lung disease progression
  • Supportive care approaches for serious viral lung infection

These trials reflect an active interest in both chronic and acute lung conditions, with a clear emphasis on better disease management and patient outcomes.

Oncology and Cancer Care

The site also contributes to research in neoplasms, including metastatic colorectal cancer, breast cancer, ovarian cancer, non-small-cell lung cancer, and gastroesophageal junction adenocarcinoma. The trials are mainly aimed at comparing treatment strategies, improving survival, and refining treatment selection in advanced or high-risk disease.

  • Studies in colorectal cancer exploring better treatment sequencing and disease control
  • Research in breast cancer focused on recurrence risk and treatment effectiveness
  • Trials in ovarian cancer and gastroesophageal cancer evaluating more effective cancer therapies

This oncology work combines treatment evaluation with efforts to improve outcomes for patients facing aggressive or recurrent cancers.

Gastroenterology and Digestive System Diseases

Clinical research in digestive system diseases includes celiac disease, colon cancer, rectal cancer, and recovery-related issues after pancreatoduodenectomy. The studies are designed to improve symptom relief, support postoperative recovery, and strengthen treatment strategies for gastrointestinal cancers.

  • Trials addressing persistent symptoms in celiac disease
  • Research on recovery and digestive complications after pancreatic surgery
  • Studies testing better approaches for colon and rectal cancer care

These projects show a broad commitment to both chronic digestive disorders and cancer-related care within the gastroenterology field.

Female Urogenital Diseases and Gynecologic Oncology

Another important area at this site is female urogenital diseases and pregnancy-related conditions, with a particular emphasis on ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. The trials are focused on testing new treatment combinations and improving disease control in advanced gynecologic cancers.

  • Studies for newly diagnosed advanced ovarian cancer
  • Research on treatment maintenance and recurrence prevention
  • Comparisons of cancer therapies to improve progression-free survival

This work supports more personalized and effective care for women with complex gynecologic malignancies.

Virus Diseases and Infection-Related Lung Research

Clinical trials in virus diseases at the site address severe respiratory infections, including HSV-1 detection in ventilated patients and other serious viral lung infections requiring oxygen support. The main goal is to evaluate therapies that may reduce complications, prevent worsening illness, and improve survival in critically ill patients.

  • Studies in intensive care patients with viral pneumonia
  • Trials testing treatments to prevent progression to more severe respiratory support
  • Research aimed at improving outcomes in hospitalized patients with viral lung infection

These investigations connect infectious disease care with critical care medicine and respiratory support.

Pathological Conditions, Signs, and Symptoms

Some trials at Romed Klinikum Rosenheim also focus on broader pathological conditions and clinical symptoms, such as treatment persistence, postoperative complications, and lung function decline. These studies are intended to better understand patient experience, support adherence, and improve everyday clinical outcomes.

  • Research on treatment persistence and patient support
  • Studies targeting postoperative digestive complications
  • Trials measuring changes in lung function and symptom burden

This area brings together practical questions from routine care and targeted clinical research to improve how patients respond to treatment.

Site Overview

assignment
29
connected trials
corporate_fare
19
sponsors
science
44
IMPs

Activity Indicator

Last 6 months

1
Trials started
0% vs previous period.
1
Trials started 6–12 months ago
29
Total trials linked
Highly Active
trending_flatStable0%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 6 therapeutic areas and 15 of 44 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 44 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
17
Sponsors (total)
19
Active sponsors
11

Sponsor Network

Top 11 by active trials.

lock +10 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +4 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
29
Outperforms 93% of sites
public
Therapeutic diversity
6areas
Outperforms 92% of sites
groups
Sponsor diversity
19sponsors
Outperforms 93% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Romed Klinikum Rosenheim

lock Showing 1 of 29 trials — the rest is available on a paid plan.

IMP list

lock Showing 1 of 44 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Bevacizumab3Unknown2019-02-182022-08-31

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.